{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "SYK",
  "name": "Stryker Corporation",
  "url": "https://frontierpicks.com/dossiers/SYK/",
  "json_url": "https://frontierpicks.com/dossiers/SYK.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Stryker's shares are more likely to lag the S&P 500 over the next three months, because the US hip and knee slowdown that cut its 2026 sales outlook on 29 October 2026 shows no end yet. The fourth-quarter report and first 2027 outlook, expected in late January 2027, settle it.",
  "invalidation_trigger": "A daily close above $330, over the 200-day moving average and the $325.87 close of 2026-11-06, which would show the shares leading again; or a first 2027 outlook, in the late-January 2027 report, calling for organic sales growth above 2026's 6.5%–7.0% range.",
  "catalyst_date": "2027-01-01",
  "catalyst_estimated": true,
  "portfolio": null,
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "caveats": [],
  "source_links": [
    {
      "title": "STRYKER CORP - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0000310764/000031076426000059/sykex991earningsq32026.htm",
      "date": "2026-10-29"
    },
    {
      "title": "Stryker lowers 2026 guidance after slowdown in hip, knee procedures",
      "url": "https://finance.yahoo.com/healthcare/articles/stryker-lowers-2026-guidance-slowdown-142323695.html",
      "date": "2026-10-30"
    },
    {
      "title": "SYK Q3 Earnings Call Highlights Softer Demand and Revised Outlook",
      "url": "https://zacks.com/stock/news/3019663/syk-q3-earnings-call-highlights-softer-demand-and-revised-outlook",
      "date": null
    },
    {
      "title": "Stryker stock: Piper Sandler raises target after surgeon survey",
      "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/stryker-stock-piper-sandler-raises-target-after-surgeon-survey/70505902",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 net sales rose 7.7% to $6.5 billion on both a reported and an organic basis; adjusted EPS rose 10.3% to $3.52 and reported EPS fell 11.7% to $1.96.",
      "source": "Stryker third-quarter 2026 results, 8-K exhibit 99.1",
      "as_of": "2026-10-29"
    },
    {
      "claim": "US knee sales grew 1.3% to $458 million and US hip sales fell 0.6% to $277 million in the third quarter of 2026.",
      "source": "Stryker third-quarter 2026 results, 8-K exhibit 99.1",
      "as_of": "2026-10-29"
    },
    {
      "claim": "Stryker set full-year 2026 organic sales growth guidance at 6.5%–7.0% and adjusted EPS guidance at $14.80–$14.90.",
      "source": "Stryker third-quarter 2026 results, 8-K exhibit 99.1",
      "as_of": "2026-10-29"
    },
    {
      "claim": "Stryker recorded a $293 million goodwill impairment in the third quarter of 2026; the adjusted operating margin was 26.2%, up 60 basis points.",
      "source": "Stryker third-quarter 2026 results, 8-K exhibit 99.1",
      "as_of": "2026-10-29"
    },
    {
      "claim": "Kevin Lobo said 'it is now clear that there is a market slowdown' in hips and knees, tying it to US insurance premiums, deductibles and pre-authorization denials.",
      "source": "MedTech Dive, 'Stryker lowers 2026 guidance after slowdown in hip, knee procedures'",
      "as_of": "2026-10-30"
    },
    {
      "claim": "Kevin Lobo steps down as chief executive at the end of 2026; chief operating officer Spencer Stiles takes over in January 2027.",
      "source": "MedTech Dive, 2026-10-30",
      "as_of": "2026-10-30"
    },
    {
      "claim": "Director Ronda E. Stryker sold 550,000 shares in the open market at an average $325.32 on 2026-11-06.",
      "source": "SEC Form 4 filed 2026-11-09",
      "as_of": "2026-11-06"
    },
    {
      "claim": "Piper Sandler kept Overweight on Stryker and raised its price target to $350 from $325 after a surgeon survey.",
      "source": "Piper Sandler note reported by Benzinga, 2026-11-09",
      "as_of": "2026-11-09"
    }
  ],
  "view_changes": [],
  "frame": {
    "as_of": "2026-11-15",
    "business": "Stryker makes and sells medical devices to hospitals and surgery centres: hip and knee implants, Mako surgical robots, trauma and spine products, surgical equipment, beds and neurovascular devices. It earns money from implant and disposable sales plus capital equipment. Revenue was $6,520 million in the quarter to 2026-09-30.",
    "change": {
      "now": "On 2026-10-29 Stryker cut its 2026 organic sales growth outlook to 6.5%–7.0% and adjusted EPS to $14.80–$14.90, citing a market-wide US hip and knee procedure slowdown (company 8-K).",
      "next": "Sales growth slowed to 7.6% in the September quarter, but adjusted operating margin rose 60 basis points to 26.2%; a $293 million goodwill impairment cut the reported operating margin to 15.9%.",
      "linked": "Zimmer Biomet (ZBH), Smith & Nephew (SNN) and Johnson & Johnson (JNJ) sell into the same slowing hip and knee market; the CMR Surgical stake moves Stryker toward Intuitive Surgical (ISRG) in soft-tissue robotics."
    },
    "priced_in": "At the 2026-11-13 close (filed inputs to 2026-10-30) the shares trade at 32.5 times earnings, 23.8 times EV/EBIT and 4.9 times sales, for an enterprise value of $129,536 million. That holds only if revenue keeps growing near the 7.6% of the latest filed quarter while the operating margin, 15.9% that quarter after an impairment, returns toward the 25.2% of the June quarter.",
    "links": {
      "customers": [],
      "suppliers": [],
      "competitors": [
        {
          "ticker": "ZBH",
          "url": null
        },
        {
          "ticker": "SNN",
          "url": null
        },
        {
          "ticker": "JNJ",
          "url": "https://frontierpicks.com/dossiers/JNJ/"
        },
        {
          "ticker": "ISRG",
          "url": "https://frontierpicks.com/dossiers/ISRG/"
        }
      ]
    }
  },
  "filed_numbers": {
    "as_of": "2026-11-17",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-17",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-10-30",
              "restated": null,
              "value_musd": 6520,
              "yoy_pct": 7.6
            },
            {
              "end": "2026-06-30",
              "filed": "2026-07-31",
              "restated": null,
              "value_musd": 6589,
              "yoy_pct": 9.4
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-11",
              "restated": null,
              "value_musd": 6020,
              "yoy_pct": 2.6
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-11",
              "restated": null,
              "value_musd": 7171,
              "yoy_pct": 11.4
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-31",
              "restated": null,
              "value_musd": 6057,
              "yoy_pct": 10.2
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-01",
              "restated": null,
              "value_musd": 6022,
              "yoy_pct": 11.1
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-10-30",
              "restated": null,
              "pct": 65.2
            },
            {
              "end": "2026-06-30",
              "filed": "2026-07-31",
              "restated": null,
              "pct": 68.3
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-11",
              "restated": null,
              "pct": 63.3
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-11",
              "restated": null,
              "pct": 64.5
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-31",
              "restated": null,
              "pct": 63.6
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-01",
              "restated": null,
              "pct": 63.8
            }
          ]
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-10-30",
              "restated": null,
              "pct": 15.9
            },
            {
              "end": "2026-06-30",
              "filed": "2026-07-31",
              "restated": null,
              "pct": 25.2
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-11",
              "restated": null,
              "pct": 15.5
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-11",
              "restated": null,
              "pct": 25.2
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-31",
              "restated": null,
              "pct": 18.7
            },
            {
              "end": "2025-06-30",
              "filed": "2025-08-01",
              "restated": null,
              "pct": 18.5
            }
          ]
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "value_musd": 997
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "four_quarters_end": "2026-09-30",
          "value_musd": 753,
          "four_quarters_musd": 3623
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "first_end": "2025-12-31",
          "value_musd": 5446
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "first_end": "2025-12-31",
          "value_musd": 873
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "first_end": "2025-12-31",
          "value_musd": 4573
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "base_end": "2025-09-30",
          "pct": -0.5
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "value_musd": 3271
        },
        "debt": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "value_musd": 14930
        },
        "net_cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "value_musd": -11659
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "value_musd": 960,
          "yoy_pct": 2.2
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "value_musd": 3693
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "value_musd": 5747
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-10-30",
          "value_musd": 23457,
          "label": "including non-controlling interests"
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-10-30",
          "value_musd": 120884.6
        },
        "enterprise_value": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-10-30",
          "value_musd": 132543.6
        },
        "ev_sales": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-10-30",
          "multiple": 5
        },
        "ev_ebit": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-10-30",
          "multiple": 24.4
        },
        "pe": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-10-30",
          "multiple": 33.4
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-10-30",
          "multiple": 5.2
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-17",
          "basis_end": "2026-09-30",
          "basis_filed": "2026-10-30",
          "pct": 3.8
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-30",
      "published": "2026-11-10",
      "short_pct_of_outstanding": 1.75,
      "days_to_cover": 2.2,
      "change_pct": 16.8
    },
    "insiders": {
      "status": "not available yet",
      "as_of": null,
      "windows": []
    }
  },
  "body_markdown": "## Current Thesis\nStryker's shares are more likely to lag the S&P 500 over the next three months. The company cut its 2026 organic sales growth outlook to 6.5%–7.0% on 2026-10-29 because hip and knee procedures slowed across the US market, and nothing dated yet shows that slowdown ending. The fourth-quarter report and first 2027 outlook, expected in late January 2027 under a new chief executive, decide the case.\n\nThird-quarter sales grew 7.7% to $6.5 billion (company 8-K, 2026-10-29), but US knees grew 1.3% to $458 million and US hips fell 0.6% to $277 million. Chief executive Kevin Lobo said on the call that \"it is now clear that there is a market slowdown.\" He tied it to higher insurance premiums, deductibles and pre-authorization denials (MedTech Dive, 2026-10-30). A slowdown driven by patients' costs is unlikely to reverse within one quarter. Management also told analysts that fourth-quarter organic growth should be broadly comparable to the third quarter's, according to Zacks' summary of the call.\n\nThe rating is Low because the shares still carry a premium multiple while growth slows. At the 2026-11-13 close they trade at 32.5 times earnings and 23.8 times enterprise value to operating profit (EV/EBIT). Profit is holding up better than sales: adjusted earnings per share (EPS) rose 10.3% to $3.52 and the adjusted operating margin widened 60 basis points to 26.2% (8-K, 2026-10-29).\n\n## Bull Case\n- **Margins absorb the slower sales.** Third-quarter gross margin was 65.2%, against 63.6% a year earlier (10-Q filed 2026-10-30). Full-year adjusted EPS guidance of $14.80–$14.90 was trimmed only modestly (8-K, 2026-10-29).\n- **The rest of the company still grows.** MedSurg and Neurotechnology sales rose 9.2% to $3.7 billion in the third quarter, against 5.7% for Orthopaedics (8-K, 2026-10-29).\n- **Analysts mostly read the slowdown as delayed demand.** Piper Sandler raised its target to $350 from $325 and kept Overweight on 2026-11-09 after a surgeon survey, still expecting mid-single-digit procedure growth through 2027. JPMorgan kept Overweight with a $340 target on 2026-10-31.\n- **Cash generation is large.** Free cash flow was $4,573 million over the four quarters to 2026-09-30, and the diluted share count fell 0.5% from a year earlier (10-Q filed 2026-10-30).\n- **Soft-tissue robotics is a new route to growth.** Stryker invested $400 million in CMR Surgical in October 2026 and became exclusive US distributor of its robot; Lobo said Stryker hopes eventually to buy the company (MedTech Dive, 2026-10-30).\n\n## Bear Case\n- **The joint replacement market has slowed.** US hips fell 0.6% and US knees grew 1.3% in the third quarter (8-K, 2026-10-29), and management called the slowdown market-wide.\n- **The outlook was cut, not trimmed.** Organic growth guidance fell to 6.5%–7.0% on 2026-10-29, and the lower bound of the earlier range was 8% or higher.\n- **Self-inflicted problems add to the market slowdown.** A cyberattack earlier in 2026 and a new software system disrupted orthopaedics selling (MedTech Dive, 2026-10-30). A $293 million goodwill impairment cut reported EPS 11.7% to $1.96 in the third quarter (8-K, 2026-10-29).\n- **A director keeps selling.** Director Ronda E. Stryker sold 550,000 shares at an average $325.32 on 2026-11-06, after selling 350,000 at an average $336.50 on 2026-08-18 and 2026-08-19 (SEC Form 4 filings). A common market view is that steady selling by a large holder weighs on a stock's price.\n- **Leadership changes during the reset.** Lobo steps down at the end of 2026 after 15 years, and chief operating officer Spencer Stiles takes over in January 2027 (MedTech Dive, 2026-10-30). The first 2027 outlook will come from the new chief executive.\n- **Debt is higher than cash.** Debt was $14,930 million against $3,271 million of cash and short-term investments at 2026-09-30 (10-Q filed 2026-10-30).\n\n## Setup & Price Structure\nThe shares closed at $309.64 on 2026-11-13, 20.5% below the 52-week intraday high of $389.33 set on 2026-03-02. They are down 6.3% over three months. The 52-week closing low is $269.75, set on 2026-09-24.\n\nThe last close sits above the 50-day moving average of $291.95 and below the 200-day moving average of $320.42 (adjusted daily closes, as of 2026-11-13). The 200-day average is the nearest level above the price that the case turns on.\n\nThe shares closed lower in each of the six sessions from $325.87 on 2026-11-06 to $309.64 on 2026-11-13. The fall began on the day of the 550,000-share director sale. It continued through Piper Sandler's target increase on 2026-11-09. For scale, the standard deviation of 63-session returns across liquid US stocks was 27% in 2026, so a 20% fall from a peak is common among US stocks this year.\n\n## Catalyst Calendar\n\n- **~2027-01-01 (est.):** Spencer Stiles succeeds Kevin Lobo as chief executive; Quest Diagnostics chief Jim Davis joins the board. The new chief executive sets the first 2027 outlook, which could reset expectations lower or confirm the slowdown as a delay.\n- **~2027-01-28 (est.):** Fourth-quarter 2026 results and first 2027 guidance. US hip and knee growth and the 2027 organic growth outlook show whether the procedure slowdown is passing or lasting; a 2027 range above 2026's 6.5%–7.0% would undercut the lag call.\n- **~2027-02-05 (est.):** Zimmer Biomet fourth-quarter 2026 results. A peer read on whether US knee and hip volumes are recovering across the market Stryker called slowing.\n\n## What Would Change Our Mind\n\nA daily close above $330, over the 200-day moving average and the $325.87 close of 2026-11-06, which would show the shares leading again; or a first 2027 outlook, in the late-January 2027 report, calling for organic sales growth above 2026's 6.5%–7.0% range.\n\n## Correlation Notes\nStryker trades with the large orthopaedic device makers that sell into the same US hip and knee market: Zimmer Biomet (ZBH), Smith & Nephew (SNN) and Johnson & Johnson's (JNJ) DePuy Synthes. Lobo described the third-quarter slowdown as market-wide on 2026-10-29. That makes these peers' fourth-quarter knee and hip numbers, due in early 2027, a direct cross-check on Stryker's own.\n\nThe case also depends on US patients' out-of-pocket costs. Lobo tied the slowdown to insurance premiums, deductibles and pre-authorization denials (MedTech Dive, 2026-10-30), so news on 2027 insurance plan costs bears on elective procedure volumes. The CMR Surgical stake puts Stryker closer to competing with Intuitive Surgical (ISRG) in soft-tissue robotics.",
  "first_seen": "2026-11-12",
  "last_analyzed": "2026-11-15T12:07:41+00:00",
  "last_synthesized": "2026-11-15",
  "date_modified": "2026-11-16",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}